GLAUKOS Corp Expense Breakdown
No Expense Breakdown for GKOS on this site yet.
- 2026-06-30: Development and Commercialization Of Ophthalmic Therapies $34.02M.
- 2025-06-30: Development and Commercialization Of Ophthalmic Therapies $26.90M.
Source checked: the stored Expense Breakdown page for GKOS.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ophthalmic Therapies |
|---|
| 2026-06-30 | $34.02M |
|---|
| 2025-06-30 | $26.90M |
|---|
General And Administrative Expense: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ophthalmic Therapies |
|---|
| 2026-06-30 | $59.45M |
|---|
| 2025-06-30 | $43.35M |
|---|
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Development and Commercialization Of Ophthalmic Therapies |
|---|
| 2026-06-30 | $656.00K |
|---|
| 2025-06-30 | $248.00K |
|---|
Research and development: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ophthalmic Therapies |
|---|
| 2026-06-30 | $32.89M |
|---|
| 2025-06-30 | $25.80M |
|---|
Selling And Marketing Expense: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ophthalmic Therapies |
|---|
| 2026-06-30 | $56.61M |
|---|
| 2025-06-30 | $40.02M |
|---|